BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 6687377)

  • 21. Exclusive alternating chemotherapy and radiotherapy in nonmetastatic inflammatory breast cancer: 20 years of follow-up.
    Bourgier C; Pessoa EL; Dunant A; Heymann S; Spielmann M; Uzan C; Mathieu MC; Arriagada R; Marsiglia H
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):690-5. PubMed ID: 21277101
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination chemoimmunotherapy of metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, and BCG.
    Hortobagyi GN; Gutterman JU; Blumenschein GR; Tashima CK; Burgess MA; Einhorn L; Buzdar AU; Richman SP; Hersh EM
    Cancer; 1979 Apr; 43(4):1225-33. PubMed ID: 445325
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chemoimmunotherapy of advanced breast cancer: prolongation of remission and survival with BCG.
    Gutterman JU; Cardenas JO; Blumenschein GR; Hortobagyi G; Burgess MA; Livingston RB; Mavligit GM; Freireich EJ; Gottlieb JA; Hersh EM
    Br Med J; 1976 Nov; 2(6046):1222-5. PubMed ID: 791447
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination chemoimmunotherapy of metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, and BCG.
    Hortobagyi GN; Gutterman JU; Blumenschein GR; Tashima CK; Burgess MA; Einhorn L; Buzdar AU; Richman SP; Hersh EM
    Cancer; 1979 Nov; 44(5):1955-62. PubMed ID: 387212
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FAC + BCG as adjuvant therapy in breast cancer: an 8-year update.
    Blumenschein GR; Buzdar AU; Hortobagyi GN
    Recent Results Cancer Res; 1984; 96():129-32. PubMed ID: 6528087
    [No Abstract]   [Full Text] [Related]  

  • 26. Phase 2 trial of primary systemic therapy with doxorubicin and docetaxel followed by surgery, radiotherapy, and adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil based on clinical and pathologic response in patients with stage IIB to III breast cancer : long-term results from the University of Texas M. D. Anderson Cancer Center Study ID97-099.
    Alvarez RH; Booser DJ; Cristofanilli M; Sahin AA; Strom EA; Guerra L; Kau SW; Gonzalez-Angulo AM; Hortobagyi GN; Valero V
    Cancer; 2010 Mar; 116(5):1210-7. PubMed ID: 20082452
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of adjuvant chemotherapy in male breast cancer.
    Patel HZ; Buzdar AU; Hortobagyi GN
    Cancer; 1989 Oct; 64(8):1583-5. PubMed ID: 2676137
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adjuvant doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in premenopausal women with axillary lymph node positive breast carcinoma.
    Bang SM; Heo DS; Lee KH; Byun JH; Chang HM; Noh DY; Choe KJ; Bang YJ; Kim SR; Kim NK
    Cancer; 2000 Dec; 89(12):2521-6. PubMed ID: 11135211
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The role of radiotherapy in the multimodal treatment of locally advanced breast carcinoma].
    Guenzi M; Scarpati D; Corvò R; Sanguineti G; Gardin G; Conte PF; Vitale V
    Radiol Med; 1990 May; 79(5):534-8. PubMed ID: 2359862
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: results from the GEICAM/2003-02 study.
    Martín M; Ruiz A; Ruiz Borrego M; Barnadas A; González S; Calvo L; Margelí Vila M; Antón A; Rodríguez-Lescure A; Seguí-Palmer MA; Muñoz-Mateu M; Dorca Ribugent J; López-Vega JM; Jara C; Espinosa E; Mendiola Fernández C; Andrés R; Ribelles N; Plazaola A; Sánchez-Rovira P; Salvador Bofill J; Crespo C; Carabantes FJ; Servitja S; Chacón JI; Rodríguez CA; Hernando B; Álvarez I; Carrasco E; Lluch A
    J Clin Oncol; 2013 Jul; 31(20):2593-9. PubMed ID: 23733779
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination chemoimmunotherapy with FAC-BCG for metastatic breast cancer: the impact of CMF maintenance chemotherapy.
    Hortobagyi GN; Blumenschein GR; Buzdar AU; Yap HY; Schell FC; Barnes BC; Burgess MA
    J Surg Oncol; 1981; 18(2):163-72. PubMed ID: 7300363
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Simultaneous combined radio-/chemotherapy of locally recurring breast cancer].
    Renner H; Lang C; Ziegler K
    Strahlentherapie; 1984 Jul; 160(7):421-4. PubMed ID: 6464045
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multimodality treatment of 128 patients with locally advanced breast carcinoma in the era of mammography screening using standard polychemotherapy with 5-fluorouracil, epirubicin, and cyclophosphamide: prognostic and therapeutic implications.
    Karlsson YA; Malmström PO; Hatschek T; Fornander TG; Söderberg M; Bengtsson NO; Jansson TE; Sjöberg SM; Bergh JC
    Cancer; 1998 Sep; 83(5):936-47. PubMed ID: 9731898
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of surgery in the combined treatment of locally advanced breast cancer.
    Canavese G; Catturich A; Battistini G; Caroti C; Pronzato P; Gardin G; Amoroso D; Bertelli G; Conte PF; Tomao S
    Oncology; 1989; 46(6):353-6. PubMed ID: 2587002
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ftorafur, adriamycin, cyclophosphamide and BCG in the treatment of metastatic breast cancer.
    Hortobagyi GN; Blumenschein GR; Tashima CK; Buzdar AU; Burgess MA; Livingston RB; Valdivieso M; Gutterman JU; Hersh EM; Bodey GP
    Cancer; 1979 Aug; 44(2):398-405. PubMed ID: 383255
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management of inflammatory carcinoma of breast with combined modality approach - an update.
    Buzdar AU; Montague ED; Barker JL; Hortobagyi GN; Blumenschein GR
    Cancer; 1981 Jun; 47(11):2537-42. PubMed ID: 6790155
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined antiestrogen and cytotoxic therapy with pseudomonas vaccine immunotherapy for metastatic breast cancer. A prospective, randomized trial.
    Hortobagyi GN; Buzdar AU; Frye D; Hug V; Fraschini G; Ames FC; Montague E; Gutterman JU; Martin RG
    Cancer; 1987 Dec; 60(11):2596-604. PubMed ID: 3315173
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial.
    Leonard RC; Lind M; Twelves C; Coleman R; van Belle S; Wilson C; Ledermann J; Kennedy I; Barrett-Lee P; Perren T; Verrill M; Cameron D; Foster E; Yellowlees A; Crown J;
    J Natl Cancer Inst; 2004 Jul; 96(14):1076-83. PubMed ID: 15265969
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long term follow-up of women treated with 16-week, dose-intensive adjuvant chemotherapy for high risk breast carcinoma.
    Mikhak B; Zahurak M; Abeloff MD; Fetting JH; Davidson NE; Donehower RC; Waterfield W; Kennedy MJ
    Cancer; 1999 Feb; 85(4):899-904. PubMed ID: 10091768
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15.
    Fisher B; Brown AM; Dimitrov NV; Poisson R; Redmond C; Margolese RG; Bowman D; Wolmark N; Wickerham DL; Kardinal CG
    J Clin Oncol; 1990 Sep; 8(9):1483-96. PubMed ID: 2202791
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.